It was patented in 1982 and approved for medical use in 1992.[2] It is on the
World Health Organization's List of Essential Medicines.[3] It is marketed by
Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel.
Tropisetron have been shown to sensitise human
α7-nicotinic receptors to low concentrations of acetylcholine, indicative of a possible co-agonist or other modulatory action of tropisetron at these receptors.[6]
Adverse effects
Tropisetron is a well-tolerated drug with few side effects.
Headache,
constipation, and
dizziness are the most commonly reported side effects associated with its use.
Hypotension, transient liver enzyme elevation, immune hypersensitivity syndromes and extrapyramidal side effects have also been associated with its use on at least one occasion. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic
cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.
hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. (February 2001). "The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist". Bioorganic & Medicinal Chemistry Letters. 11 (3): 319–321.
doi:
10.1016/S0960-894X(00)00670-3.
PMID11212100.
^Cui R, Suemaru K, Li B, Kohnomi S, Araki H (May 2009). "Tropisetron attenuates naloxone-induced place aversion in single-dose morphine-treated rats: role of alpha7 nicotinic receptors". European Journal of Pharmacology. 609 (1–3): 74–77.
doi:
10.1016/j.ejphar.2008.12.051.
PMID19374878.
It was patented in 1982 and approved for medical use in 1992.[2] It is on the
World Health Organization's List of Essential Medicines.[3] It is marketed by
Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel.
Tropisetron have been shown to sensitise human
α7-nicotinic receptors to low concentrations of acetylcholine, indicative of a possible co-agonist or other modulatory action of tropisetron at these receptors.[6]
Adverse effects
Tropisetron is a well-tolerated drug with few side effects.
Headache,
constipation, and
dizziness are the most commonly reported side effects associated with its use.
Hypotension, transient liver enzyme elevation, immune hypersensitivity syndromes and extrapyramidal side effects have also been associated with its use on at least one occasion. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic
cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.
hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. (February 2001). "The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist". Bioorganic & Medicinal Chemistry Letters. 11 (3): 319–321.
doi:
10.1016/S0960-894X(00)00670-3.
PMID11212100.
^Cui R, Suemaru K, Li B, Kohnomi S, Araki H (May 2009). "Tropisetron attenuates naloxone-induced place aversion in single-dose morphine-treated rats: role of alpha7 nicotinic receptors". European Journal of Pharmacology. 609 (1–3): 74–77.
doi:
10.1016/j.ejphar.2008.12.051.
PMID19374878.